SEC Company Response from Tempest Therapeutics, Inc. (TPST) (CIK 0001544227) (TPST) — Dec 3, 2018
Tempest Therapeutics, Inc. (TPST) (CIK 0001544227)
Date: Dec. 3, 2018 · CIK: 0001544227 · Accession: 0001104659-18-071132
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228209
Letter
OvaScience, Inc.
9 Fourth Avenue
Waltham, Massachusetts 02451
December 3, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
RE: OvaScience, Inc.
Registration Statement on Form S-3 File No. 333-228209
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, OvaScience, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-228209), as amended (the “Registration Statement”), so that it may become effective at 9:00 a.m., Washington, D.C. time on December 6, 2018, or as soon as possible thereafter.
The Company hereby authorizes Megan N. Gates, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Ms. Gates at (617) 348-4443 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Ms. Gates.
Very truly yours,
OVASCIENCE, INC.
Show Raw Text
CORRESP 1 filename1.htm OvaScience, Inc. 9 Fourth Avenue Waltham, Massachusetts 02451 December 3, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor RE: OvaScience, Inc. Registration Statement on Form S-3 File No. 333-228209 Request for Acceleration of Effectiveness Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, OvaScience, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-228209), as amended (the “Registration Statement”), so that it may become effective at 9:00 a.m., Washington, D.C. time on December 6, 2018, or as soon as possible thereafter. The Company hereby authorizes Megan N. Gates, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration. The Company respectfully requests that it be notified of such effectiveness by a telephone call to Ms. Gates at (617) 348-4443 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Ms. Gates. Very truly yours, OVASCIENCE, INC. /s/ Jonathan Gillis Jonathan Gillis Senior Vice President, Finance cc: OvaScience, Inc. Christopher A. Kroeger., M.D., M.B.A., President and Chief Executive Officer Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. William C. Hicks, Esq. Megan N. Gates, Esq. Daniel A. Bagliebter, Esq. Cooley, LLP Miguel J. Vega, Esq. Nicole Brookshire, Esq.